본문 바로가기
KERD
논문KCI 등재

Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China

Renwen Zhang|Cuiping Shao|Na Huo, Minran Li|Xiaoyuan Xu
거트앤리버 소화기연관학회협의회|2016.05|Gut and Liver|제10권 제3호|pp. 446-455

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

IL28BInterferon-γ-inducible-protein-10Viral responsePegylated interferon α-2a plus ribavirin

초록

Background/Aims: Several studies have demonstrated that serum interferon-γ-inducible-protein-10 (IP-10) levels at baseline and single nucleotide polymorphisms (SNPs) near the IL28B gene were associated with viral response and treatment outcomes. Our purpose was to assess the combination of pretreatment IP-10 levels with IL28B SNPs as predictors of treatment response to pegylated interferon α-2a plus ribavirin in patients infected with genotype 1 hepatitis C virus in China. Methods: Seventy-two patients with chronic hepatitis C without fibrosis/cirrhosis were enrolled in the study. The virologic parameters and baseline serum IP-10 levels were determined. IL-28B genotypes were determined by sequencing. Results: In this cohort, serum baseline IP-10 levels lower than 426.7 pg/mL could predict rapid virological response/ sustained virological response (SVR). Patients carrying favorable IL28B SNP genotypes had higher SVRs than did those carrying unfavorable variants (IL28B rs12979860, p=0.002; IL28B rs8099917, p=0.020). Combining both baseline IP- 10 and IL28B SNPs could improve the prediction of SVR in favorable allele carriers of IL28B, rs12979860 CC and rs8099917 TT. Serum baseline IP-10 levels and IL28B genotypes were independent predictors of SVR. Conclusions: Our study shows that the combination of baseline serum IP-10 levels and the determination of IL28B SNPs increase the predictability of SVR rates in this cohort.

Abstract

Background/Aims: Several studies have demonstrated that serum interferon-γ-inducible-protein-10 (IP-10) levels at baseline and single nucleotide polymorphisms (SNPs) near the IL28B gene were associated with viral response and treatment outcomes. Our purpose was to assess the combination of pretreatment IP-10 levels with IL28B SNPs as predictors of treatment response to pegylated interferon α-2a plus ribavirin in patients infected with genotype 1 hepatitis C virus in China. Methods: Seventy-two patients with chronic hepatitis C without fibrosis/cirrhosis were enrolled in the study. The virologic parameters and baseline serum IP-10 levels were determined. IL-28B genotypes were determined by sequencing. Results: In this cohort, serum baseline IP-10 levels lower than 426.7 pg/mL could predict rapid virological response/ sustained virological response (SVR). Patients carrying favorable IL28B SNP genotypes had higher SVRs than did those carrying unfavorable variants (IL28B rs12979860, p=0.002; IL28B rs8099917, p=0.020). Combining both baseline IP- 10 and IL28B SNPs could improve the prediction of SVR in favorable allele carriers of IL28B, rs12979860 CC and rs8099917 TT. Serum baseline IP-10 levels and IL28B genotypes were independent predictors of SVR. Conclusions: Our study shows that the combination of baseline serum IP-10 levels and the determination of IL28B SNPs increase the predictability of SVR rates in this cohort.

참고문헌 (40)

  1. Mohd Hanafiah K, "Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence", Hepatology, 57, pp.1333~1342 (2013)
  2. Lavanchy D, "The global burden of hepatitis C", Liver Int, 29(1), pp.74~81 (2009)
  3. Ly KN, "The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007", Ann Intern Med, 156, pp.271~278 (2012)
  4. McHutchison JG, "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group", N Engl J Med, 339, pp.1485~1492 (1998)
  5. Yu ML, "Treatment of chronic hepatitis C in Asia:when East meets West", J Gastroenterol Hepatol, 24, pp.336~345 (2009)
  6. Hadziyannis SJ, "Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
  7. Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
  8. Yu ML, "A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C", Gut, 56, pp.553~559 (2007)
  9. Diago M, "Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C", Gut, 55, pp.374~379 (2006)
  10. Lagging M, "IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection", Hepatology, 44, pp.1617~1625 (2006)
  11. Romero AI, "Interferon (IFN)-gammainducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection", J Infect Dis, 194, pp.895~903 (2006)
  12. Abe T, "CD44 participates in IP-10induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan", J Virol, 86, pp.6159~6170 (2012)
  13. Larrubia JR, "The role of CCR5", CXCR3expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection, 2007, pp.47, 632~641
  14. Butera D, "Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C", Blood, 106, pp.1175~1182 (2005)
  15. Darling JM, "Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response", Hepatology, 53, pp.14~22 (2011)
  16. Matsuura K, "Serum interferon-gammainducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C", Hepatol Res, 44, pp.1208~1216 (2014)
  17. Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
  18. Tanaka Y, "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C", Nat Genet, 41, pp.1105~1109 (2009)
  19. Beinhardt S, "Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection", Gastroenterology, 142(e2), pp.78~85 (2012)
  20. Lagging M, "Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms", PLoS One, 6, pp.e17232~ (2011)
  21. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, "Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection", J Gastroenterol Hepatol, 22, pp.615~633 (2007)
  22. Nie HM, "Genotypes distribution of hepatitis C virus through multi-center, large sample studies among chronic hepatitis C patients in Chinese Han population", Zhonghua Liu Xing Bing Xue Za Zhi, 33, pp.501~504 (2012)
  23. Wang LF, "Prevalence of abnormal glycometabolism in patients with chronic hepatitis C and related risk factors in China", Chin Med J, 124, pp.183~188 (2011)
  24. Bai L, "Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China", Chin Med J, 122, pp.5~9 (2009)
  25. Zeremski M, "Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus", HIV-coinfected patients, 2007, pp.45, 262~268
  26. Kurelac I, "Chemokine CXCL10 at week 4 of treatment predicts sustained virological response in patients with chronic hepatitis C", J Interferon Cytokine Res, 32, pp.386~391 (2012)
  27. Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus", Nature, 461, pp.798~801 (2009)
  28. Helbig KJ, "Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation", Hepatology, 39, pp.1220~1229 (2004)
  29. Itoh Y, "Clinical significance of elevated serum interferon-inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels", J Viral Hepat, 8, pp.341~348 (2001)
  30. Zeremski M, "Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C", Hepatology, 48, pp.1440~1450 (2008)
  31. Heydtmann M, "Chemokines in the immunopathogenesis of hepatitis C infection", Hepatology, 49, pp.676~688 (2009)
  32. Chan Ran You, "Serum IP-10 Levels Correlate with the Severity of Liver Histopathology in Patients Infected with Genotype-1 HCV", Gut and Liver, 5(4), pp.506~512 (2011), 거트앤리버 발행위원회
  33. Reiberger T, "IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection", Antivir Ther, 13, pp.969~976 (2008)
  34. Askarieh G, "Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the firstphase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C", Hepatology, 51, pp.1523~1530 (2010)
  35. Feld JJ, "Plasma interferon-gammainducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection", PLoS One, 8, pp.e80003~ (2013)
  36. Fattovich G, "IL28B polymorphisms, IP-10and viral load predict virological response to therapy in chronic hepatitis C", Aliment Pharmacol Ther, 33, pp.1162~1172 (2011)
  37. Feld JJ, "Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response", Hepatology, 46, pp.1548~1563 (2007)
  38. Wang J, "Association of interferon-gamma-induced protein-10 serum levels with virological responses to PEG-interferon-based therapy in hepatitis C virus genotype 1 or 2 chronically infected Chinese patients", Scand J Gastroenterol, 49, pp.1349~1358 (2014)
  39. Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
  40. Tsubota A, "Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load", J Med Virol, 75, pp.27~34 (2005)

관련 논문AI추천

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients김강모, 서동진, 심주현, 안지현, 이단비, 이영상, 이우창, 이한주, 임영석, 허내윤대한간학회 · Clinical and Molecular Hepatology2014 · 제20권 제2호Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection길호, 김영석, 김진욱, 민보영, 변영상, 우병현, 이연재, 정숙향거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제1호Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C권오상, 김윤수, 김종우, 김주현, 박상진, 양재원, 정석후, 정영걸, 최덕주대한간학회 · Clinical and Molecular Hepatology2012 · 제18권 제4호Serum IP-10 Levels Correlate with the Severity of Liver Histopathology in Patients Infected with Genotype-1 HCV박수형, 배시현, 성영철, 우현영, 윤승규, 장정원, 최종영, Chan Ran You, Sung Won Jeong, Young Chul Sung거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제4호Prediction of a Null Response to Pegylated Interferon α-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis CAkira Kawashima, Hideyuki Tamai, Hisanobu Deguchi, Izumi Inoue, Jun Kato, Kazuki Ueda, Kosaku Moribata, Masanori Kawaguchi, Masao Ichinose, Mikitaka Iguchi, Naoki Shingaki, Takao Maekita, Yoshiyuki Mori, Yuki Wada거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제4호유전자형 1형 만성 C형 간염 환자에서 혈청 인터페론감마유도단백질-10의 의미고진성, 김선원, 김재선, 김지훈, 김태형, 박영태, 박종재, 변관수, 연종은, 이범재, 이영선, 이준영, 이현정, 임상아, 윤아일린대한내과학회 · 대한내과학회지2010 · 제79권 제6호

이 간행물의 다른 논문 (25건)

The Garlic Preparation as an Alternative Way for Gastroprotection: From Bench to ClinicJong-Jae Parkpp. 321-322Helicobacter pylori Eradication, a Gordian Knot for Idiopathic Thrombocytopenic Purpura?김태호, 정대영pp. 323-324Mast Cell May Be the Master Key to Solve the Mystery of Pathogenesis of Irritable Bowel SyndromeHyuk Yoonpp. 325-326Patients’ Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus WesternHyungil Seo, Byong Duk Yepp. 327-329The Mental Health State of Quiescent Inflammatory Bowel Disease PatientsYoon Tae Jeen, Sung Chul Parkpp. 330-331
원문 보기